Literature DB >> 2948307

In vitro immunosuppressive properties of cyclosporine metabolites.

B M Freed, T G Rosano, N Lempert.   

Abstract

The in vitro biological activity of cyclosporine (CsA) and four of its metabolites (M1, M8, M17, and M21) was determined. M1, M17, and M21 are primary metabolites, while M8 is a secondary metabolite derived from either M1 or M17. The order of inhibitory activity in production assays was phytohemagglutinin (PHA), concanavalin A (ConA), mixed lymphocyte culture (MLC), and interleukin-2 (IL-2) CsA greater than M17 greater than M1 greater than M21 much greater than M8. In the PHA assay, CsA was significantly more inhibitory than M17, but in Con A and MLC assays, the inhibitory activity of M17 approached that of CsA. More importantly, M17 and M1 inhibited the production of IL-2 in the MLC to the same extent as CsA. M21 was significantly less inhibitory than either M17 or M1, and M8 appeared to be largely devoid of biological activity. These experiments demonstrate that single hydroxylations of amino acids 1 (M17) and 9 (M1) do not significantly affect the ability of the molecule to block IL-2 production, but hydroxylation of both amino acids renders the molecule virtually inactive. In addition, the presence of the N-methyl group on amino acid 4 appears to be very important, since removal of this group (M21) greatly diminishes the immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2948307     DOI: 10.1097/00007890-198701000-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Cyclosporine Metabolite Profiles in the Blood of Liver Transplant Patients.

Authors:  C P Wang; G J Burckart; R Venkataramanan; R J Ptachcinski; R E Cuellar; L Makowka; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  [Effect of diltiazem on blood cyclosporin levels].

Authors:  U Kunzendorf; G Walz; H H Neumayer; K Wagner; F Keller; G Offermann
Journal:  Klin Wochenschr       Date:  1987-11-16

5.  The influence of cyclosporine A treatment on immune responsiveness in vitro and in vivo in kidney transplant recipients.

Authors:  A A van der Heyden; M H van Oers; P Cornelissen; S L Yong; J M Wilmink; P T Schellekens
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

6.  Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients.

Authors:  C P Wang; G J Burckart; R J Ptachcinski; R Venkataramanan; T Schwinghammer; T Hakala; B Griffith; R Hardesty; R Shadduck; J Knapp
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

7.  Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells.

Authors:  A Zeevi; G Eiras; G Burckart; L Makowka; R Venkataramanan; C P Wang; D H Van Thiel; N Murase; T E Starzl; R Duquesnoy
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

Review 8.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

9.  A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

Authors:  A Lindholm; R Dahlqvist; G G Groth; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

10.  Pharmacokinetic interaction between cyclosporin and diltiazem.

Authors:  J Brockmöller; H H Neumayer; K Wagner; W Weber; G Heinemeyer; H Kewitz; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.